The KP.2 sub-variant of COVID-19, which has become increasingly prevalent on a global scale, is unlikely to cause a new ...

For a large percentage of men with prostate cancer, the tumor may be so slow-growing that doctors advise a "watch-and-wait" ...

The number of registered nurses in China reached 5.63 million by the end of 2023, according to data released by the National ...

Researchers may have developed a new, improved way to test for the most serious and aggressive forms of prostate cancer.A new ...

Purpose. The pharmacology, efficacy, safety, and dosage and administration of bendamustine and its use in indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are reviewed.

Answered by Dr. Howard E. Lewine M.D. Chief Medical Editor, Harvard Health Publishing · 40 years of experience · USA ...

Ogun State Governor, Prince Dapo Abiodun, has described the past five years of his administration as challenging, but added ...

Doubeni noted that finding an indolent cancer creates challenges with current screening methods. Brewer said the numbers of ...

A new study finds that for people with low-grade prostate cancer, active surveillance is effective for management of the ...

Half of men with low-risk prostate cancer remained free from progression or treatment 10 years after diagnosis when followed ...

CNTY-101 is being assessed in heavily pre-treated relapsed or refractory NHL patients with predominantly aggressive or high-risk indolent histologies who have received two to five prior therapies, ...